2019年7月24日 · New World Health Organization (WHO) recommendations, released on 22 July 2019 at IAS 2019, include dolutegravir (DTG) as the preferred antiretroviral drug in first- and second-line regimens. This recommendation recognises the declining estimate DTG-associated neural tube defect risk and observed efficacy.

2024年6月27日 · The Once-daily DTG based ART in Young people vS Standard thErapY (ODYSSEY) trial, conducted by the Pediatric European Network for the Treatment of AIDS (PENTA), enrolled both treatment-naive and treatment-experienced pediatric patients from the European Union, Thailand, and several African countries; this trial initially evaluated doses ...

2024年3月21日 · Integrase strand transfer inhibitors (INSTIs) are the latest class of ART drugs that have been developed to target HIV enzymes [9] and are recommended for the treatment of ART-experienced and ART-naïve patients [10]. Dolutegravir (DTG), a second generation INSTI, has demonstrated both high efficacy and a high barrier to resistance [11].

2023年9月14日 · 多替拉韦/拉米夫定（DTG/3TC）仅可用于HIV RNA＜500,000拷贝/mL且未合并HBV感染的HIV感染者，不可用于未获得基因型耐药检测结果前的快速启动 [6-8]，如有暴露前预防（PrEP）失败史，不建议将此方案作为ART启动方案 [8]。 指南推荐的基于INSTI的ART方案，不同方案在临床试验和真实世界研究中产生耐药的HIV感染者比例以及对治疗产生的影响也有所差别。 5项探索比克替拉韦/恩曲他滨/丙酚替诺福韦（B/F/TAF）与其他三联ART方案的疗效非劣效 …

2023年10月10日 · The widespread use of the integrase strand transfer inhibitor (INSTI) dolutegravir in first-line and second-line antiretroviral therapy (ART) might facilitate emerging resistance. The DTG RESIST study combined data from HIV cohorts to examine patterns of drug resistance mutations (DRMs) and identify risk factors for dolutegravir resistance.

2024年6月27日 · Dolutegravir (DTG) plus ritonavir-boosted darunavir (DRV/r) and DTG with tenofovir disoproxil fumarate (TDF) plus lamivudine (3TC) or emtricitabine (FTC) are both noninferior to DRV/r plus 2 nucleoside reverse transcriptase inhibitors (NRTIs) for HIV virologic suppression in patients who experience treatment failure on non-NRTI (NNRTI)-based ...

2019年10月1日 · The use of DTG-based ART regimens in patients coinfected with TB and HIV lead to favorable TB and HIV treatment outcomes, comparable to those achieved with alternative ART regimens. Our results provide reassurance to TB and HIV programs about the overall programmatic concomitant use of these first-l …

2023年4月5日 · Background: The widespread use of the integrase strand transfer inhibitor (INSTI) dolutegravir (DTG) in first- and second-line antiretroviral therapy (ART) may facilitate emerging resistance. We combined data from HIV cohorts to examine patterns of drug resistance mutations (DRMs) and identify risk factors for DTG resistance.

2022年8月3日 · Dolutegravir (DTG)-based ART achieved and mostly maintained viral load suppression in children and adolescents in real-world settings in seven sites in six African countries. These findings from a retrospective chart review, conducted by Baylor International Pediatric AIDS Initiative, were presented at AIDS 2022.

2021年11月13日 · In 2019, the World Health Organisation (WHO) recommended Dolutegravir (DTG) as the preferred first-line antiretroviral treatment (ART) for all persons with HIV. ART regimen switches may affect HIV treatment adherence. We sought to describe patient experiences switching from EFV to DTG-based ART in Kampala, Uganda.